Bladder SPOREs
Bladder cancer will have an estimated 82,290 new cases and 16,710 deaths in 2023 according to the NCI's Surveillance, Epidemiology, and End Results Program (SEER)*. The percent of patients surviving for 5 years is 77.9%. The incidence rate is about 4 times higher in men than in women and 2 times higher in White men than in Black men. The Memorial Sloan Kettering Cancer Center Bladder SPORE was funded in 2018 with goals to 1) Develop predictive biomarkers based on patients' response or resistance to chemotherapy and immunotherapy, 2) Access a large set of familial patient samples (>1000) and use genome sequencing technologies to identify novel inherited susceptibility genes, 3) Understand why patients treated with immunotherapy (anti PD-L1) have limited response and find predictive markers of response and resistance to guide combination therapies, and 4) Explore immunologic predictors of BCG immunotherapy.
*Bladder Cancer Statistics: https://seer.cancer.gov/statfacts/html/urinb.html